MacroGenics(NASDAQ) MGNX

MacroGenics, Inc. makes medicines to help doctors treat cancer. It uses engineering to create antibodies that find and attack cancer cells. These treatments aim to give patients better ways to fight diseases.

The Antibody Toolkit

• Antibody-Drug Conjugates: Treatments like MGC026 and MGC028 that deliver cell-killing payloads directly to cancer targets.
• Multispecific Antibodies: Proprietary DART and TRIDENT molecules designed to bind to multiple targets simultaneously.
• Licensed Medicines: FDA-approved therapies like ZYNYZ and TZIELD that are marketed by partners while generating royalties.
• Immune Checkpoint Inhibitors: Clinical-stage molecules like lorigerlimab that help the immune system recognize and destroy cancer cells.

Strategic Deals and Decisions

• Sold the contract manufacturing business to Bora Pharmaceuticals in July 2026 for $122.5 million.
• Secured a $24.5 million regulatory milestone payment from Sanofi related to the drug TZIELD, expected in Q3 2026.
• Expanded a research agreement with Gilead Sciences in August 2026 to license a new research molecule.
• Received over $1.6 billion in funding through strategic collaborations with global pharmaceutical companies since 2000.

What Sets the Technology Apart?

The company uses proprietary engineering platforms to create antibodies that can bind to multiple cancer targets at once. It balances internal research with strategic partnerships to fund its clinical trials.

The Financial Scorecard

• Total revenue was $32.8 million for the three months ended June 30, 2026, up 378% year over year.
• Royalty revenue reached $7.3 million for the three-month period ended June 30, 2026, up 462% year over year.
• Research and development expense was $38.8 million for the quarter ended June 30, 2026, down 5% year over year.
• Net income from discontinued operations was $89.1 million for the three months ended June 30, 2026.
• The accumulated deficit reached $1.3 billion as of June 30, 2026.

Bottom Line

MacroGenics has transitioned from a manufacturer to a focused drug developer by selling its production facilities. Its future depends on advancing its antibody pipeline and collecting milestones from its global partners.